Faron Pharmaceuticals Ltd - Turku, Finland-based clinical stage biopharmaceutical company - US Food & Drug Administration and Finnish Medicines Agency clear company's investigational new drug application to start its BEXMAB study, which is for assessing the safety, tolerability and efficacy of precision cancer immunotherapy known as bexmarilimab.
"Research has shown a clear survival benefit among certain blood cancer patients with low Clever-1 expression, a receptor known to be expressed on immunosuppressive macrophages in the tumor microenvironment. By adding bexmarilimab to standard of care we expect to downregulate Clever-1 expression, thereby increasing antigen presentation and allowing the immune system to better identify and kill cancer cells," said Chief Medical Officer Marie-Louise Fjallskog.
Current stock price: 235.00 pence
12-month change: down 36%
By Dayo Laniyan; dayolaniyan@alliancenews.com
Copyright 2022 Alliance News Limited. All Rights Reserved.
Faron Pharma (FARN)